Rainbow Rare Earths Phalaborwa project shaping up to be one of the lowest cost producers globally. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNippon Active . Regulatory News (NAVF)

Share Price Information for Nippon Active . (NAVF)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 169.00
Bid: 168.00
Ask: 169.00
Change: 0.50 (0.30%)
Spread: 1.00 (0.595%)
Open: 167.50
High: 169.00
Low: 167.50
Prev. Close: 168.50
NAVF Live PriceLast checked at -
Nippon Active Value is an Investment Trust

To provide Shareholders with attractive capital growth through the active management of a focussed portfolio of quoted companies which have the majority of their operations in, or revenue derived from, Japan and that have been identified by the Investment Adviser as being undervalued.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Proposed Fundraise

22 Oct 2021 07:00

RNS Number : 8831P
Nippon Active Value Fund PLC
22 October 2021
 

THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, THE REPUBLIC OF SOUTH AFRICA, JAPAN, ANY MEMBER STATE OF THE EUROPEAN ECONOMIC AREA OR ANY JURISDICTION IN WHICH IT WOULD BE UNLAWFUL TO DO SO

 

This announcement contains inside information.

LEI: 213800JOFEGZJYS21P75

Nippon Active Value Fund plc

Proposed Fundraise

Nippon Active Value Fund plc (the "Company") announces that it is proposing to raise further capital to pursue its proven model of activist investment in quoted Japanese companies. Accordingly, the Board plans to implement a share issuance programme to raise capital for further investment through the issue of up to 300 million Ordinary Shares or C Shares (together, the "Shares") over the next 12 months following the publication of the necessary prospectus (the "Share Issuance Programme"). The Share Issuance Programme will include an initial issue which is expected to comprise an initial placing, offer for subscription and intermediaries offer (the "Initial Issue").

The implementation of the Share Issuance Programme requires the publication of a Prospectus and Circular both of which the Company expects to publish in the near term. Any decision to proceed with the publication of the Prospectus and Circular, or to proceed with either an issue of Ordinary Shares or C Shares, is at the absolute discretion of the Directors and will be subject to prevailing market conditions and investor sentiment.

Should the Company decide to proceed with such publication, a further announcement will be made in due course. A further announcement will also be made on reaching a decision to issue either Ordinary Shares or C Shares under the Initial Issue.

Introduction

The Company was launched in February 2020 with the IPO raising £103 million, which has subsequently been invested. The performance of the Company since IPO has demonstrated proof of the original concept. The Share Issuance Programme is designed to grow the size of individual holdings and should further enhance the effectiveness of the Company's investment strategy. Currently, no constraints on the ability of putting much larger amounts of capital to work are envisaged.

The proceeds of the Share Issuance Programme will be used for investment in accordance with the Company's investment policy and to fund the Company's operational expenses. The intention is to invest the proceeds of the Share Issuance Programme substantially within the universe of investment targets identified by the Investment Adviser. This will facilitate larger holdings and accelerate the process of engaging with management. It is probable that some further names, within the universe of suitable companies already identified, will be added over time.

The Share Issuance Programme

The Initial Issue

The Company is proposing to issue up to 150 million new Ordinary Shares or C Shares pursuant to the Initial Issue which is expected to comprise an Initial Placing, Offer for Subscription and Intermediaries Offer. In the event that the Directors decide to proceed with an issue of Ordinary Shares, the issue price for the new Ordinary Shares will be determined by the Company and will be not less than the prevailing Net Asset Value per Ordinary Share at the time of announcement of the issue price plus a premium intended, together with premia over the course of the Placing Programme, to cover the fixed costs of the Initial Issue. In the event that the Directors decide to proceed with an issue of C Shares, the issue price for the C Shares will be £1.00.

The actual number of Ordinary Shares or C Shares to be issued pursuant to the Initial Issue will be notified by the Company via a Regulatory Information Service prior to Initial Admission.

Shareholder approval for the Initial Issue will be sought at a General Meeting of the Company. The Company expects to publish a Circular convening the General Meeting in the near term.

Subsequent Issues

Following the Initial Issue, the Directors intend to implement a Placing Programme to raise capital for further investment.

The Directors intend to seek authority at a General Meeting to issue, following the Initial Issue, up to 300 million Ordinary Shares or C Shares pursuant to each issue of Shares following the Initial Issue (the "Subsequent Issues") (less the number of Ordinary Shares or C Shares issued pursuant to the Initial Issue), without having to first offer those Shares to existing Shareholders.

The issue price for any new Ordinary Shares to be issued pursuant to a Subsequent Issue will be determined by the Company and will be not less than the prevailing Net Asset Value per Ordinary Share at the time of issue plus a premium to cover the expenses of such issue. The issue price for any C Shares to be issued pursuant to a Subsequent Issue will be not less than £1.00.

For the avoidance of doubt, the authority to issue up to 300 million Ordinary Shares or C Shares is intended to cover issues of both class of share, and not to confer authority to issue 300 million Ordinary Shares and 300 million C Shares.

The authority to allot further Shares sought in connection with the Share Issuance Programme will, if passed, lapse on the date on which the Placing Programme closes.

Costs of the Proposals

Any Ordinary Shares issued pursuant to the Initial Issue or a Subsequent Issue will be issued at a price not less than the last published NAV per Ordinary Share at the time of issue, together with a premium intended to cover the expenses of the issue. The issue price will also take into consideration the prevailing share price per Ordinary Share.

Any C Shares issued pursuant to the Initial or a Subsequent Issue will be issued at £1.00. The costs of the relevant issue of such C Shares will be paid out of the proceeds of the issue and accordingly will be borne indirectly by investors in the relevant C Shares.

Benefits of the Proposals

The Directors believe that the Proposals will have the following benefits for Shareholders:

· the Company will be able to raise additional funds in a timely manner to enable it to take advantage of opportunities to make further investments in accordance with its investment policy;

· the Company will be able to increase its holding in portfolio companies, as well as initiating new positions, which is expected to accelerate the process of engaging with management;

· the market capitalisation of the Company will increase, helping to make the Company attractive to a wider investor base, including to those investors who have expressed a preference for investing in larger investment trusts;

· a greater number of Ordinary Shares in issue (either following an issue of Ordinary Shares or a conversion of C Shares into Ordinary Shares) should improve liquidity in the secondary market for the Ordinary Shares and make the Ordinary Shares more attractive to a wider range of investors; and

· the Company's fixed running costs will be spread across a larger equity capital base, which should reduce the level of ongoing expenses per Ordinary Share.

Considerations associated with the Proposals

Shareholders should have regard to the following when considering the Proposals:

· the Share Issuance Programme is not being made on a pre-emptive basis. Shareholders who do not, or cannot, participate in any issue under the Share Issuance Programme for an amount at least pro rata to their existing holding will have their percentage holding diluted;

· there can be no guarantee that the Company will ultimately be able to make further investments in accordance with its investment policy on satisfactory terms, or at all; and

· Shareholders should be aware that the past performance of the Company or of the Investment Manager is not necessarily indicative of likely future performance.

Timetable

A Prospectus and Circular are expected to be published in the near term and will set out the timetable for the above proposals in full.

 

Enquiries:

 

Shore CapitalRobert Finlay / Rose Ramsden (Corporate)Adam Gill / Matthew Kinkead (Sales)Henry Willcocks / Fiona Conroy (Corporate Broking)

020 7408 4050

PraxisIFM Fund Services (UK) LimitedTom Daish / Sylvanus Cofie

020 4513 9260

Media EnquiriesAlex Gorokhov

020 3040 0892

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
IOEPPGMPUUPGPGG
Date   Source Headline
21st Jun 202411:26 amRNSNet Asset Value(s)
20th Jun 202412:00 pmRNSNet Asset Value(s)
19th Jun 202412:00 pmRNSNet Asset Value(s)
18th Jun 202412:00 pmRNSNet Asset Value(s)
17th Jun 202412:00 pmRNSNet Asset Value(s)
14th Jun 202412:35 pmRNSMonthly Factsheet
14th Jun 202412:00 pmRNSNet Asset Value(s)
13th Jun 202412:00 pmRNSNet Asset Value(s)
13th Jun 202411:14 amRNSParticipation in Webinar
12th Jun 202412:00 pmRNSNet Asset Value(s)
11th Jun 202412:00 pmRNSNet Asset Value(s)
10th Jun 202412:00 pmRNSNet Asset Value(s)
10th Jun 202410:23 amRNSParticipation in AIC Roundtable Webinar
7th Jun 20243:05 pmRNSNet Asset Value(s)
7th Jun 202411:59 amRNSResult of AGM
6th Jun 202412:00 pmRNSNet Asset Value(s)
5th Jun 202412:00 pmRNSNet Asset Value(s)
4th Jun 202412:00 pmRNSNet Asset Value(s)
3rd Jun 202412:10 pmRNSNet Asset Value(s)
31st May 202410:20 amRNSNet Asset Value(s)
30th May 202412:40 pmRNSNet Asset Value(s)
29th May 202412:00 pmRNSNet Asset Value(s)
28th May 202412:00 pmRNSNet Asset Value(s)
24th May 20242:00 pmRNSNet Asset Value(s)
23rd May 202412:00 pmRNSNet Asset Value(s)
22nd May 202412:00 pmRNSNet Asset Value(s)
21st May 202412:00 pmRNSNet Asset Value(s)
20th May 20243:31 pmRNSMonthly Factsheet
20th May 202412:00 pmRNSNet Asset Value(s)
17th May 202412:00 pmRNSNet Asset Value(s)
16th May 202412:00 pmRNSNet Asset Value(s)
15th May 202412:00 pmRNSNet Asset Value(s)
14th May 202412:00 pmRNSNet Asset Value(s)
13th May 202412:00 pmRNSNet Asset Value(s)
10th May 202412:00 pmRNSNet Asset Value(s)
9th May 20241:33 pmRNSNet Asset Value(s)
8th May 202412:00 pmRNSNet Asset Value(s)
7th May 202412:00 pmRNSNet Asset Value(s)
3rd May 202412:00 pmRNSNet Asset Value(s)
2nd May 202412:00 pmRNSNet Asset Value(s)
1st May 202412:00 pmRNSNet Asset Value(s)
30th Apr 202412:00 pmRNSNet Asset Value(s)
29th Apr 202412:00 pmRNSNet Asset Value(s)
26th Apr 202412:00 pmRNSNet Asset Value(s)
25th Apr 202412:00 pmRNSNet Asset Value(s)
24th Apr 202412:00 pmRNSNet Asset Value(s)
23rd Apr 202412:00 pmRNSNet Asset Value(s)
22nd Apr 202412:00 pmRNSNet Asset Value(s)
19th Apr 202412:18 pmRNSNet Asset Value(s)
18th Apr 202411:49 amRNSNet Asset Value(s)

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.